Abstract
Tasimelteon (Hetlioz®) is a dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) (free-running disorder). In two randomized, double-masked, multicentre, phase III trials, totally blind individuals with Non-24 who received oral tasimelteon 20 mg once nightly were significantly more likely than those receiving placebo to entrain the circadian pacemaker (the SET trial) and maintain entrainment (the RESET trial). Sleep/wake parameters and functioning were also improved with tasimelteon. Oral tasimelteon was generally well tolerated in totally blind patients with Non-24. In conclusion, tasimelteon is a useful drug for the treatment of Non-24 in totally blind individuals.
Similar content being viewed by others
References
Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. Sleep. 2007;30(11):1460–83.
Uchiyama M, Lockley SW. Non-24-hour sleep-wake rhythm disorder in sighted and blind patients. Sleep Med Clin. 2015;10(4):495–516.
Brown GM. Light, melatonin and the sleep-wake cycle. J Psychiatry Neurosci. 1994;19(5):345–53.
Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science. 2002;295(5557):1070–3.
Burgess HJ, Eastman CI. Human tau in an ultradian light-dark cycle. J Biol Rhythms. 2008;23(4):374–6.
Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284(5423):2177–81.
Eastman CI, Molina TA, Dziepak ME, et al. Blacks (African Americans) have shorter free-running circadian periods than whites (Caucasian Americans). Chronobiol Int. 2012;29(8):1072–7.
Torres R, Kramer WG, Baroldi P. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. J Clin Pharmacol. 2015;55(5):525–33.
Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD): an update for 2015. J Clin Sleep Med. 2015;11(10):1199–236.
Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. Sleep. 2007;30(11):1484–501.
Liu J, Clough SJ, Hutchinson AJ, et al. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–83.
European Medicines Agency. Hetlioz (tasimelteon): EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 22 Feb 2016.
Vanda Pharmaceuticals Inc. Hetlioz® (tasimelteon) capsules, for oral use: US prescribing information. 2014. http://www.hetlioz.com/pdf/HetliozPI.pdf. Accessed 22 Feb 2016.
Lavedan C, Forsberg M, Gentile AJ. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015;91:142–7.
European Medicines Agency. Hetlioz (tasimelteon): EU assessment report. 2015. http://www.ema.europa.eu. Accessed 22 Feb 2016.
Rajaratnam SMW, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373(9662):482–91.
Lavedan C, Torres R, Sliman JA, et al. Assessment of potential for withdrawal or abuse with the use of the circadian regulator tasimelteon [abstract no. 0481]. Sleep. 2014;37(Suppl):A168.
Feeney J, Birznieks G, Scott C, et al. Melatonin agonist tasimelteon improves sleep in primary insomnia characterized by difficulty falling asleep [abstract no. 0127]. Sleep. 2009;32(Suppl):A43.
Leger D, Quera-Salva M-A, Vecchierini M-F, et al. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf. 2015;14(11):1673–85.
Torres R, Dressman MA, Kramer WG, et al. Absolute bioavailability of tasimelteon. Am J Ther. 2015;22(5):355–60.
Ogilvie BW, Torres R, Dressman MA, et al. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015;55(9):1004–11.
Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386(10005):1754–64.
Quera-Salva MA, Dressman M, Perry C, et al. A multicenter open-label safety study of tasimelteon for the treatment of non-24-hour sleep-wake disorder in blind individuals with no light perception [abstract no. P433]. J Sleep Res. 2014;23(Suppl 1):127.
Eastman C. Entraining the free-running circadian clocks of blind people. Lancet. 2015;386(10005):1713.
Burgess HJ, Revell VL, Molina TA, et al. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab. 2010;95(7):3325–31.
Lockley SW, Skene DJ, James K, et al. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol. 2000;164(1):R1–6.
Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343(15):1070–7.
Hack LM, Lockley SW, Arendt J, et al. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms. 2003;18(5):420–9.
Cardinali DP, Golombek DA, Rosenstein RE, et al. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse. Pharmacol Res. 2015. doi:10.1016/j.phrs.2015.08.016.
European Medicines Agency. Circadin (prolonged-release melatonin): EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 22 Feb 2016.
Takeda Pharmaceuticals America Inc. Rozerem (ramelteon): US prescribing information. 2010. http://www.rozerem.com. Accessed 22 Feb 2016.
Stahl SM. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectr. 2014;19(6):475–8.
Acknowledgments
During the peer review process, the manufacturer of tasimelteon was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
Gillian Keating is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information
The manuscript was reviewed by: C.I. Eastman, Biological Rhythms Research Laboratory, Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA; I. Fietze, Center of Sleep Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany; T.J. Swick, Department of Neurology, University of Texas School of Medicine-Houston, Houston, TX, USA; J.M. Zeitzer, Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.
Rights and permissions
About this article
Cite this article
Keating, G.M. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs 30, 461–468 (2016). https://doi.org/10.1007/s40263-016-0330-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-016-0330-y